<DOC>
	<DOCNO>NCT01956149</DOCNO>
	<brief_summary>Single-arm study determine disease control rate second- ( later ) line treatment cabazitaxel failure palliative primary treatment .</brief_summary>
	<brief_title>Study With Cabazitaxel Previously Treated Patients With Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description>65 patient advanced metastatic adenocarcinoma oesophagogastric junction stomach treat 20mg/m2 Cabazitaxel maximum 6 cycle . Main objective study Disease Control Rate ( DCR ) Cabazitaxel .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm inoperable and/or metastatic adenocarcinoma oesophagogastric junction stomach 2 . Progression measurable lesion ( RECIST ) previous palliative chemotherapy . Neoadjuvant/adjuvant treatment count , unless progression occur &lt; 6 month completion treatment . In case , neoadjuvant/adjuvant treatment count one line . 3 . Male female patient age &gt; 18 year 4 . ECOG ≤ 1 5. neutrophil ≥ 1500/µl 6 . Haemoglobin ≥ 9 g/dl 7 . Platelets ≥ 100,000/µl 8 . AST/SGOT and/or ALT/SGPT ≤2.5 x ULN ; 9 . Total bilirubin ≤1.0 x ULN 10 . Serum creatinine ≤ 1.5 time normal value , creatinine clearance ≥ 60 ml/min 11 . Written patient inform consent 1 . A history severe hypersensitivity taxanes ( ≥ grade 3 ) medicinal product contain polysorbate 80 ( ≥ grade 3 ) 2 . Active CAD , cardiomyopathy NYHA stage IIIIV heart failure 3 . Malignant secondary disease date back &lt; 5 year ( exception : situ cervical carcinoma , appropriately treat basal cell carcinoma skin ) 4 . Severe secondary internal disease , include uncontrolled diabetes mellitus acute infection 5 . Concomitant medication plan treatment strong CYP450 3A4/5 inducer inhibitor ( list medicinal product appendix ) relevant medicinal product discontinue minimum one week treatment 6 . Peripheral polyneuropathy &gt; NCI grade II 7 . Severe hepatic impairment ( AST/ALT &gt; 2.5 x ULN , , bilirubin &gt; 1 x ULN ) 8 . Chronic inflammatory bowel disease 9 . Participation another study 10 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>second-line treatment</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>response</keyword>
</DOC>